Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02229214 · ClinicalTrials.gov registry record · Phase 4
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
A Phase 4 study, sponsored by VIVUS.
- Completed
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT02229214 is a Phase 4 study that has completed, run by VIVUS. The registered enrollment target is 51 participants.
The verdict
NCT02229214, a Phase 4 study, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of off-treatment recovery.
Interventions
- DRUG Placebo
- DRUG Qsymia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2014-08 |
| Est. Completion | 2014-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02229214
The ClinicalTrials.gov registry entry for NCT02229214 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02229214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02229214 about?
NCT02229214 is a clinical study titled "Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects". The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of off-treatment recovery.
What is the current status of trial NCT02229214?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2014-08. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02229214?
The interventions under investigation include: Placebo (DRUG), Qsymia (DRUG).
Who is sponsoring clinical trial NCT02229214?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.